Literature DB >> 26806087

Dermatomyositis With or Without Anti-Melanoma Differentiation-Associated Gene 5 Antibodies: Common Interferon Signature but Distinct NOS2 Expression.

Yves Allenbach1, Gaëlle Leroux2, Xavier Suárez-Calvet3, Corinna Preusse4, Eduard Gallardo3, Baptiste Hervier5, Aude Rigolet2, Miguel Hie6, Debora Pehl4, Nicolas Limal7, Peter Hufnagl8, Norman Zerbe8, Alain Meyer9, Jessie Aouizerate10, Yurdagul Uzunhan11, Thierry Maisonobe12, Hans-Hilmar Goebel4, Olivier Benveniste5, Werner Stenzel4.   

Abstract

The anti-melanoma differentiation-associated gene 5 (MDA5) autoantibody is specifically associated with dermatomyositis (DM). Nevertheless, anti-MDA5(+)-patients experience characteristic symptoms distinct from classic DM, including severe signs of extramuscular involvement; however, the clinical signs of myopathy are mild or even absent. The morphological and immunological features are not yet described in adulthood. Data concerning the pathophysiology of anti-MDA5 DM are sparse; however, the importance of the interferon (IFN) type I pathway involved in DM has been shown. Our aim was to define morphological alterations of the skeletal muscle and the intrinsic immune response of anti-MDA5-positive DM patients. Immunohistological and RT-PCR analysis of muscle biopsy specimens from anti-MDA5 and classic DM were compared. Those with anti-MDA5 DM did not present the classic features of perifascicular fiber atrophy and major histocompatibility complex class I expression. They did not show significant signs of capillary loss; tubuloreticular formations were observed less frequently. Inflammation was focal, clustering around single vessels but significantly less intense. Expression of IFN-stimulated genes was up-regulated in anti-MDA5 DM; however, the IFN score was significantly lower. Characteristic features were observed in anti-MDA5 DM and not in classic DM patients. Only anti-MDA5 DM showed numerous nitric oxide synthase 2-positive muscle fibers with sarcoplasmic colocalization of markers of regeneration and cell stress. Anti-MDA5-positive patients demonstrate a morphological pattern distinct from classic DM.
Copyright © 2016 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26806087     DOI: 10.1016/j.ajpath.2015.11.010

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  25 in total

Review 1.  Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis.

Authors:  Wanlong Wu; Li Guo; Yakai Fu; Kaiwen Wang; Danting Zhang; Wenwen Xu; Zhiwei Chen; Shuang Ye
Journal:  Clin Rev Allergy Immunol       Date:  2021-01-06       Impact factor: 8.667

Review 2.  MDA5 autoantibody-another indicator of clinical diversity in dermatomyositis.

Authors:  Richard D Sontheimer
Journal:  Ann Transl Med       Date:  2017-04

Review 3.  Type I Interferons in Autoimmunity.

Authors:  Ruth Fernandez-Ruiz; Timothy B Niewold
Journal:  J Invest Dermatol       Date:  2022-01-10       Impact factor: 8.551

Review 4.  Dermatomyositis Clinical and Pathological Phenotypes Associated with Myositis-Specific Autoantibodies.

Authors:  Paige W Wolstencroft; David F Fiorentino
Journal:  Curr Rheumatol Rep       Date:  2018-04-10       Impact factor: 4.592

Review 5.  Management of Interstitial Lung Disease in Patients With Myositis Specific Autoantibodies.

Authors:  Christopher A Mecoli; Lisa Christopher-Stine
Journal:  Curr Rheumatol Rep       Date:  2018-04-10       Impact factor: 4.592

Review 6.  Updates on the Immunopathology in Idiopathic Inflammatory Myopathies.

Authors:  Akinori Uruha; Hans-Hilmar Goebel; Werner Stenzel
Journal:  Curr Rheumatol Rep       Date:  2021-07-01       Impact factor: 4.592

Review 7.  Anti-MDA5 Antibody Spectrum in Western World.

Authors:  Siamak Moghadam-Kia; Chester V Oddis; Rohit Aggarwal
Journal:  Curr Rheumatol Rep       Date:  2018-10-31       Impact factor: 4.592

8.  213th ENMC International Workshop: Outcome measures and clinical trial readiness in idiopathic inflammatory myopathies, Heemskerk, The Netherlands, 18-20 September 2015.

Authors:  Olivier Benveniste; Lisa G Rider
Journal:  Neuromuscul Disord       Date:  2016-05-27       Impact factor: 4.296

9.  Diagnostic muscle biopsies in the era of genetics: the added value of myopathology in a selection of limb-girdle muscular dystrophy patients.

Authors:  Boel De Paepe; Elise Velghe; Linnea Salminen; Balint Toth; Pieter Olivier; Jan L De Bleecker
Journal:  Acta Neurol Belg       Date:  2021-01-05       Impact factor: 2.396

Review 10.  Autoimmune Myopathies: Where Do We Stand?

Authors:  Jean-Philippe Simon; Isabelle Marie; Fabienne Jouen; Olivier Boyer; Jérémie Martinet
Journal:  Front Immunol       Date:  2016-06-14       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.